Surgical outcomes of nephrectomy for elderly patients with renal cell carcinoma
Xiaomin Gao1, Liang Hu2, Yue Pan3, Lei Zheng4

ABSTRACT
Objective: The feasibility of curative surgery for elderly patients with renal cell carcinoma (RCC) remains controversial and under discussion. The main aim of this study was to evaluate the long-term benefits of curative surgery as a treatment for RCC in elderly patients.
Methods: We retrospectively considered 672 patients with RCC who underwent partial nephrectomy or radical nephrectomy between January 2004 and July 2014. X-tile program was used to determine the optimal age cutoff values with CSS as endpoint.
Results: Patients were divided into the following groups according to their age using the method of X-tile program: a young group (< 40 years), a young-old group (40-75) and an old-old group (≥ 75). Following multivariate analysis age ≥ 75 years was determined to be an independent risk factor for overall survival (HR=4.36; 95% CI: 1.31-14.48; P=0.016); interestingly, this was not the case for cancer-specific survival (HR = 2.65; 95% CI: 0.77-9.16; P=0.124). Furthermore, an age of 40 to 75 years was not a risk factor according to univariate and multivariate analysis.
Conclusion: After determining the age cutoff values, there was no significant difference in prognosis between young and old patients with RCC.

KEYWORDS: Age groups, Nephrectomy, Renal cell carcinoma, Survival.

INTRODUCTION
Renal cell carcinoma (RCC) is well-known as the most common renal parenchymal malignancy, representing 2% to 3% of all cancers.1 In 2013, more than 350, 000 cases and 140, 000 deaths from RCC occurred worldwide.2 Like other common genitourinary carcinomas, RCC typically affects older patients; in fact, only 5% of all RCC patients are younger than 40 years old and the median age at diagnosis remains between 60 and 65 years.3,4 The incidence of RCC varies worldwide; notably, as the overall Chinese population ages and the average Chinese lifespan gradually increases,5,6 the number of elderly patients in China who have been diagnosed with malignancy continues to increase. In spite of the advances that have been made in the understanding of RCC biology, surgery procedures, including radical nephrectomy or partial nephrectomy, remain the only curative treatment method for localized RCC patients.1,7 Older patients
are generally considered to have decreased reserve capacity and a higher risk and incidence of adverse outcomes after surgery. Therefore, surgeons often hesitate to perform surgery for elderly RCC patients, due to the high frequency of mortality and complications.8-11

Recently, several studies have been completed that have evaluated the long-term benefits of curative surgery in old patients with non-metastatic RCC. Focusing on these individuals’ long-term survival, some studies have reported that there was no notable statistical difference in prognosis between young and old patients with RCC,4,12,13 these authors found that elderly patients could benefit from the curative surgery, and yielded cancer-specific survival (CSS) rates similar to those of young patients. On the other hand, there have been other studies that have emphasized that elderly patients had worse CSS rates compared with young patients.3,4,14-16 Therefore, the feasibility of curative surgery for elderly patients with RCC remains controversial and under discussion. Furthermore, the patient ages in these studies were inconsistent, with ranges of 40-79, 60-70, 60-80, and ≥ 75 years considered, respectively. In this retrospective study, we evaluate the clinicopathological features and survival outcomes of patients undergoing curative nephrectomy at different ages, in an attempt to find possible associated factors and appropriate age cut-off values to predict the prognosis of RCC patients after surgery.

METHODS

Study design and population: Consecutive RCC patients who underwent radical or partial nephrectomy from January 2004 to July 2014 at the Urologic Department of The First Affiliated Hospital of Wenzhou Medical University, China, were included in this study. This study was approved by the ethics committee of The First Affiliated Hospital of Wenzhou Medical University.

Clinical data, including clinicopathologic and hematologic records, were collected and retrospectively analyzed. Overall survival (OS) and CSS were calculated from the date of surgery to the date of all-cause death, cancer-specific death, or the last follow-up date, respectively. Information on the occurrence of death was obtained from a telephone interview, outpatient medical records, or the patient’s social security death index. The primary endpoint of this study was CSS, and the follow-up cutoff was September 1, 2016.

Statistical analysis: X-tile program (Version 3.6.1, Yale University, New Haven, CT, USA) was used to determine the optimal age values. The continuous data that were subjected to normal distribution were presented as mean ± standard deviation, and the non-normally distributed data were estimated as median and interquartile range (IQR). Two sample independent t tests (Mann-Whitney U-test for non-normally distributed data) and chi-square test or Fisher’s exact test were used to test for differences in continuous and categorical variables, respectively. Kaplan-Meier survival curves with log-rank tests and Cox proportional hazard regression analyses were used to compare the OS and CSS rates. Variables with p<0.05 in the univariate Cox regression analysis were included in the multivariate analysis. All tests were two-sided, and differences were considered statistically significant at p<0.05. Statistical analyses were performed using the SPSS software package version 22.0 (IBM Corp., Armonk, NY, USA).

RESULTS

Grouping: From January 2004 to July 2014, a total of 672 patients were included in our study. These patients were divided into 6 groups according to their age distribution (< 40, 40-49, 50-59, 60-69, 70-79, ≥ 80 years, respectively). According to Fig.1 A, B, the OS rate decreased with advancing age; sharp and slight variations were observed at 75 years using the X-tile program (Fig.S1). The χ² log-rank value of the age was 23.2087. The age of 40 years was used to discriminate between young and old patients in most previous studies; therefore, the patients in the current study were divided into three groups: a young group (< 40 years), a young-old group (40-75) and an old-old group (≥ 75).

Among the 672 patients with RCC, 70 (10.4%), 490 (72.9%), and 112 (16.7%) were aged < 40, 40-75, and ≥ 75 years old, respectively (Fig.1). These patients’ clinical and pathological features are detailed in Table-I. There were no significant differences in terms of patient sex, tumor size, pathological T stage, and tumor grade among the three groups. However, ASA grade III (16.3%, 5.25, and 1.4%, respectively; p< 0.001) and lower BMI (22.3, 23.3, and 23.4, respectively; p = 0.009) were more common in the old-old group than in the other two groups. Although the tumor size was comparable among the three age groups (4.0, 4.3, and 4.3, respectively; p = 0.172), patients aged ≥ 75 years old were more likely to undergo radical nephrectomy, rather than partial nephrectomy, as compared with young-old group or young group patients (85.4%, 76.8%, and 68.6%, respectively; p = 0.021). Additionally, there
were significant differences in histologic subtype among the non-metastatic RCC patients according to age (p=0.001). Specifically, patients in the young-old or old-old groups were diagnosed with clear cell RCC more often than patients in the young group (88.5%, 88.6%, and 75.7%, respectively; p=0.010). In contrast, patients in the young group were more likely to have chromophobe histology as compared with patients in the young-old or old-old groups (17.1%, 5.4%, and 4.1%, respectively; p<0.001).

During the follow-up period, 61 patients (9.1%) died, with 41 of them (6.1%) dying from cancer-specific causes within 10 years of follow-up. The median follow-up duration was 50.8 months (IQR 30.4-86.1, mean 59.6). As shown in Fig.2, patients aged ≥ 75 years old had a poorer OS and CSS than patients aged < 40 years old or patients aged 40-75 years old (p<0.001); however, the OS (p=0.808) and CSS (p=0.773) rates were comparable between patients aged < 40 years old and patients aged 40-75 years old. The 5-year OS and CSS rates were 95.7% and 95.7%, respectively, for patients in the young group patients; 94.0% and 95.7%, respectively, for patients in the young-old group patients; and 76.0% and 81.8%, respectively, for patients in the old-old group. Table-II shows the results of univariate and multivariate analysis of factors correlated with OS and CSS. Age (≥ 75 years vs. < 40 years) was an independent risk factor for OS (HR = 4.36; 95% CI: 1.31-14.48; P=0.016), but was not significantly associated with death from RCC (HR=2.65; 95% CI: 0.77-9.16; P=0.124). Moreover, BMI, tumor size, T stage, and tumor grade were also independent predictors for OS and CSS.
DISCUSSION

The incidence of elderly patients diagnosed with RCC has significantly increased worldwide in the past few decades, primarily due to overall population aging; and in many countries, this is a known major public health problem whose resolution is considered urgent. However, though several studies have reported on the association between age and prognosis in RCC, there is still some controversy among experts with regards to the specifics of the relationship. This contention may be due to the inconsistent age classifications utilized in different studies examining patients with RCC (specifically, 40-79, 60-70, 60-80, ≥ 75 years). Therefore, unlike what was done in previous studies, in this study, we evaluated the outcomes of RCC patients after surgery as the first step in stratifying them, and then compared their clinicopathological characteristics, which allowed us to identify significant differences.

Previous studies have demonstrated that patients aged < 40 years old with other malignancies such as breast cancer generally have worse CSS after surgery as compared with older patients with the same. However, our results do not show this in
Table-II: Univariate and multivariate logistic regression analysis of risk factors for OS and CSS.

|          | OS Univariate analysis | Multivariate analysis |
|----------|------------------------|-----------------------|
|          | HR (95% CI), P value   | HR (95% CI), P value  |
| Sex (male) | 1.59 (0.91-2.78), 0.107 | 1.24 (0.37-4.09), 0.730 |
| Age       |                        |                       |
| Young-old/Young | 1.19 (0.36-3.93), 0.775 | 1.24 (0.37-4.09), 0.730 |
| Old-old/Young  | 5.46 (1.67-17.84), 0.005 | 4.36 (1.31-14.48), 0.016 |
| ASA grade (≥ III) | 3.31 (1.75-6.25), < 0.001 | 1.70 (0.87-3.31), 0.122 |
| BMI (≥ 25)  | 0.28 (0.11-0.69), 0.006 | 0.32 (0.13-0.81), 0.016 |
| Type of surgery (Partial nephrectomy) | 0.50 (0.21-1.16), 0.106 | 2.12 (1.21-3.72), 0.009 |
| Mean tumor size (≥ 7) | 2.85 (1.69-4.81), < 0.001 | 2.73 (1.47-5.07), 0.002 |
| Pathological T stage (≥ 3) | 4.04 (2.28-7.18), < 0.001 | 2.12 (1.27-3.54), 0.004 |
| Fuhrman grade (≥ 3)  | 2.92 (1.76-4.83), < 0.001 | 2.12 (1.27-3.54), 0.004 |
| Histologic subtype (Clear cell) | 1.07 (0.69-1.67), 0.766 | 1.07 (0.69-1.67), 0.766 |
| CSS       |                        |                       |
| Sex (male) | 0.97 (0.52-1.82), 0.927 | 0.86 (0.25-2.93), 0.807 |
| Age (≥ 65)  |                        |                       |
| Young-old/Young | 0.84 (0.25-2.86), 0.782 | 0.86 (0.25-2.93), 0.807 |
| Old-old/Young  | 3.58 (1.06-12.04), 0.040 | 2.65 (0.77-9.16), 0.124 |
| ASA grade (≥ III) | 3.43 (1.58-7.43), 0.002 | 1.82 (0.80-4.13), 0.153 |
| BMI (≥ 25)  | 0.36 (0.11-1.15), 0.037 | 0.42 (0.15-1.19), 0.101 |
| Type of surgery (Partial nephrectomy) | 0.36 (0.11-1.15), 0.085 | 0.67 (0.20-2.26), 0.521 |
| Mean tumor size (≥ 7) | 4.33 (2.34-8.00), < 0.001 | 2.85 (1.46-5.56), 0.002 |
| Pathological T stage (≥ 3) | 5.37 (2.77-10.39), < 0.001 | 3.14 (1.53-6.44), 0.002 |
| Fuhrman grade (≥ 3)  | 3.79 (2.03-7.07), < 0.001 | 2.58 (1.37-4.87), 0.003 |
| Histologic subtype (Clear cell) | 1.09 (0.65-1.82), 0.749 | 1.09 (0.65-1.82), 0.749 |

the case of RCC patients. Although older patients were found to have significant poorer OS rates after surgery than those < 40 years of age, there was no statistical difference with respect to CSS between these two groups on multivariate analysis. The results of our study are comparable to those of previous reports. The Mayo Clinic previously conducted a retrospective review from 1970 to 2000, in which they evaluated the CSS rates of 124 patients aged 18 to 40 years old and 1067 patients aged 60 to 70 years old. Their results revealed that no statistical significance was observed in these two groups. Thompson et al. also described the results of a study in which 1,720 RCC patients were enrolled from 1989 to 2005 and divided into three age groups: < 40 years, 40-59 years, and 60-79 years. The authors reported that they did not observe a significant difference in CSS according to age. Recently, Kim et al. investigated the influence of age at diagnosis on CSS in RCC, and performed propensity score matching to adjust for potential baseline confounders. Their data showed that young RCC patients presented with better CSS than older patients did before the two groups were matched, and that the CSS appeared to be similar in the matched cohort. This study employed minimum inherent selection using the analysis of propensity score matching that may help to address the controversy on the feasibility of curative surgery for old patients. In our study, we performed an investigation using the method of X-tile program to identify significant differences. However, patients in the old-old group patients still failed to demonstrate a significantly poorer CSS than patients in the young group. Therefore, considering the worse OS and similar CSS rates of older RCC patients that are present following curative surgery, the selection of surgery candidates should not merely be based
on chronological age, but should also consider the patient’s life expectancy and functional status. When considering the confounding factors, young-old age was not a risk predictor for OS and CSS rates, indicating that patients aged 40-75 years old would likely receive the same benefit from surgery as patients aged < 40 years old.

Therefore, in this setting, two hypotheses may be considered. First, according to the world Health Organization’s 2014 World Health Report, the average life expectancy of Chinese individuals has sharply increased during the past decade.[6] We speculate that CSS rates have improved in older patients because most of them have lived long enough to benefit from surgery. Second, should the selection of candidates who will be treated with nephrectomy take only their life expectancy and functional status into consideration, despite them being elderly? In other words, should age not be considered as important in estimating the prognosis of RCC patients after surgery? Unfortunately, no current study can reliably examine such hypotheses, and it remains to be tested in a prospective randomized trial. However, our results do suggest the necessity for older patients to be treated with nephrectomy to avoid the potential risk.

There are several limitations in the present study. First, this study was conducted at a single center and was retrospective in nature. However, we believe our data to be representative and reliable because our department is the largest urologic cancer center with the largest sample size for RCC patients in the southern part of Zhejiang Province. Second, the sample size of the young-old group and old-old group was relatively small, and the number of deaths recorded was small, possibly in part because of the short follow-up period employed. Both of these may led to a relatively high survival rate in our reported results. Third, cancer-specific mortality rate can be a confounding factor because elderly patients can die due to reasons other than cancer progression. Therefore, this needed to be taken into consideration when comparing the three age groups, and all the authors agree that it is one of the limitations of this study. In conclusion, our results suggest that there was no significant difference in prognosis between young and old patients with RCC.

Acknowledgement: All of authors thank Editage for English language editing. This work received the grant from the Medical Scientific Research Items of Wenzhou people’s hospital [grant number 2017ZD004].

Declaration of Interest: The authors declare that they have no conflicts of interest.

REFERENCES

1. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67:913-924. doi: 10.1016/j.eururo.2015.01.008

2. Ferlay J, Shin EM, Dikshit R. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2013. http://globocan.iarc.fr (Accessed Jan 1, 2015). 604-612. http://globocan.iarc.fr (accessed Jan 1, 2015),604-612

3. Taccoen X, Valeri A, Descotes JL, Morin V, Stindel E, Doucet L, et al. Renal cell carcinoma in adults 40 years old or less: young age is an independent prognostic factor for cancer-specific survival. Eur Urol. 2007;51:980-987. doi: 10.1016/j.eururo.2006.10.025

4. Gillet MD, Cheville JC, Kames RJ, Lobie CM, Kwon ED, Leibovich BC, et al. Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses. J Urol. 2005;173:1893-1896. doi: 10.1097/01.ju.0000158157.57981.80

5. Chen W, Zheng R, Baade PD, Zhang S, Zong H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115-132. doi: 10.3322/caac.21338.

6. Organization WH. Global health observatory data repository. Life expectancy data by country. doi: 10.3322/cac.21235.

7. Capitanio U, Montorsi F. Renal cancer. Lancet. 2016;387:894-906. doi: 10.1016/S0140-6736(15)00046-X

8. Vetterlein MW, Jindal T, Becker A, Regier M, Kluth LA, Tilki D, et al. Small renal masses in the elderly: Contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies. Investig Clin Urol. 2016;57:231-239. doi: 10.4111/icu.2016.57.4.231

9. Sun M, Becker A, Tian Z, Rughmann F, Abdollah F, Larouche A, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. 2014;65:235-241. doi: 10.1016/j.eururo.2013.03.034.

10. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, Larson BT, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010;116:3119-3126. doi: 10.1002/cncr.25158.

11. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331-1334. doi: 10.1093/jnci/djl362.

12. Thompson RH, Ordonez MA, Isacson A, Secin FP, Guillonneau B, Russo P, et al. Renal cell carcinoma in young and old patients—is there a difference? J Urol. 2008;179:1262-1266. doi: 10.1016/j.juro.2007.06.037.

13. Kim JH, Park YH, Kim YJ, Kang SH, Byun SS, Hong SH. Is there a difference in clinicopathological outcomes of renal tumor between young and old patients? A multicenter matched-pair analysis. Scand J Urol. 2010;44:387-391. doi: 10.1080/03012638.2010.1162462.

14. Denzinger S, Otto W, Burger M, Hammerschmidt C, Junker K, Hartmann A, et al. Sporadic renal cell carcinoma in young and elderly patients: are there different clinicopathological features and disease specific survival rates? World J Surg Oncol. 2007;5:16. doi: 10.1186/1477-7819-5-16.

15. Jung EJ, Lee HJ, Kwak C, Ku JH, Moon KC. Young age is independent prognostic factor for cancer-specific survival of low-stage clear cell renal cell carcinoma. Urology. 2009;73:137-141. doi: 10.1016/j.urology.2008.08.460.

16. Sanchez-Ortiz RF, Rosser CJ, Madsen LT, Swanson DA, Wood CG. Young age is an independent prognostic factor for survival of sporadic renal cell carcinoma. J Urol. 2004;171:2160-2165. doi:10.1097/01.ju.0000158157.57981.80.

17. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996;77:97-103. doi: 10.1002/(sici)1097-0248(19960101)77:1<97::aid-cncr18>3.0.co;2-3.

18. de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993;341:1039-1043. doi: 10.1016/0140-6736(93)92407-k.

Authors’ Contribution: XG: The idea of topic, manuscript writing; LH: Acquisition of the data; YP: Analysis and interpretation of the data; LZ: Study designed and submission of manuscript.